Previous 10 | Next 10 |
Summary Harrow is a slow and steady seller of various ophthalmic products. In the last few months, it has gone up considerably. I expect more from the company, although I am still trying to figure out their strengths and weaknesses. I covered Harrow Health ( HROW )...
Harrow Health Inc. ( NASDAQ: HROW ) fell 4.8% after a new short report from Bonitas Research about the eyecare pharmaceutical company. Bonitas claims that company has issues with "risks disclosures" and "quality control standards," according to the report. Bonitas said it's sh...
Summary SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated 35.31% during 2022. 2023 stock market returns will be determined by the direction of earnings. Dear Partners, SRK Fund I, LP apprec...
Formulations Do Not Contain Preservatives or Boric Acid, Have a Physiologic pH of 5.5, and May Be Stored at Room Temperature For Up to 180 Days Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the launch of its patent-pending, next-generation compoun...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent, product-specific J-code for IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. ...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products: ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®. ...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the availability, for in-office use, of Fortisite™ ( compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility. For...
Summary As December 2022 comes to a close, we observe six new preferred stock / exchange-traded-debt (ETD) offerings during the month, offering annual yields ranging from 6.75% to 11.875%. Here is a comparison against the highest quality preferred stocks in our coverage universe, as ran...
MELT-300 Statistically Superior for Procedural Sedation Compared to All Comparator Treatment Arms, Including Midazolam 3mg (P=0.0129) and Ketamine 50mg (P=0.0096) MELT-300 Treatment Arm 50% Less Likely to Require Rescue Sedation Compared to Midazolam (P=0.0198) MELT-300 Treatm...
Announces Pricing of $35 Million Aggregate Principal Amount Offering of 11.875% Senior Notes Due 2027 Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription ther...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...